Address And Details

82 Devonshire St , Boston, MA 02109
Fund Manager Robert Regan
Manager Tenure 3 Years

Strategy And Objective

The fund seeks to provide investment results that correspond to the total return of stocks of mid- to small-capitalization U.S. companies. Normally investing at least 80% of assets in common stocks included in the Fidelity U.S. Extended Investable Market Indexâ„ , which is a float-adjusted market capitalization-weighted index designed to reflect the performance of U.S. mid- and small-cap stocks. Mid- and small-cap stocks are considered to be stocks of the top 2,500 U.S. companies, excluding the largest 500 companies, based on float-adjusted market capitalization.

Net Asset Value

as of 5:13 PM ET 09/24/2021

Performance

  • 1 Week
  • +0.88%
  • 1 Month
  • +0.44%
  • 3 Months
  • -0.87%
  • 1 Yr Return
  • +52.61%
  • 5 Yr Return
  • n/a

Equity Sector Breakdown

Finance 21.10%
IndustrialCyclical 14.42%
Technology 13.80%
Health 9.10%
NonDurables 7.95%
RetailTrade 7.80%
Services 6.50%
ConsumerDurables 4.99%
Utilities 3.25%
Energy 1.95%

Asset Allocation

Asset Type % Of Allocation
Stocks 99.77%
ForeignStocks 1.11%
Cash 0.00%
Bonds 0.00%
Preferred 0.00%
Convertible 0.00%
Other 0.00%
ForeignBonds 0.00%
ForeignHedged 0.00%
Total Net Assets 1.33 B

Risk Measures

Criteria 3 Years 5 Years 10 Years
Alpha n/a n/a n/a
Beta n/a n/a n/a
R Squared n/a n/a n/a
Std Deviation n/a n/a n/a
Sharpe Ratio n/a n/a n/a

Purchase Information

as of 5:22 PM ET 09/23/2021
Minimum Initial $0
Minimum Additional $0
Minimum Initial IRA $0

Performance

Timeframe Average Annual Current Performance Monthly As Of 08/31/2021 Average Annual Current Performance Quarterly As Of 06/30/2021 Avg Annual Current Performance Monthly As Of 08/31/2021 Avg Annual Current Performance Quarterly As Of 06/30/2021
1 Year
  • +48.25%
  • +60.87%
+48.25% +60.87%
3 Year
  • n/a
  • n/a
n/a n/a
10 Year
  • n/a
  • n/a
n/a n/a
Life Of Fund
  • +13.32%
  • +13.94%
+13.32% +13.94%

Top 10 Holdings

Symbol Company Name % Of Assets
LB L BRANDS INC 0.25%
WHR WHIRLPOOL CORP 0.24%
XRAY DENTSPLY SIRONA INC 0.24%
MOH MOLINA HEALTHCARE INC 0.24%
FANG ~DIAMONDBACK ENERGY INC 0.24%
CCK CROWN HOLDINGS INC 0.24%
WRK WESTROCK COMPANY 0.24%
TXT TEXTRON INC 0.23%
SBNY SIGNATURE BANK 0.23%
JBHT HUNT (JB) TRANSPRT SVCS INC 0.23%

Recent Articles from TheStreet

China Power Firms Suspend Publication Of Coal Data, Frustrating Analysis Of Industrial Production

Jim Cramer's Read on Industrial Production

Latest data remains encouraging for economy.

United Airlines

United Airlines Faces Department of Transportation Fine

United Airlines faces a $1.9 million fine from the Department of Transportation for violating federal statutes and a DOT rule prohibiting long tarmac delays.

NYSE Trader Lead

Jim Cramer IDs an Underappreciated Investing Rule

It's not enough to just identify stocks you want to own.

Home Construction, and Regional and Community Bank ETFs Reflect a Healthy Housing Market

Jim Cramer Says Latest Housing Data is Mixed for Millenials

There are signs more rental units are being built, but single family dwellings are still tight.

Closing Bell: Rite Aid Spikes on FTC Negotiations; U.S. Stocks Fall

Rite Aid Teams With Uber Eats for Nationwide On-Demand Delivery

Rite Aid expands its on-demand delivery options, adding a partnership with Uber Technologies to deliver products nationwide through Uber Eats.

Amazon Prime Lead

Whole Foods Adds Service Fee for Amazon Prime Deliveries

Amazon's Whole Foods Market is ending free deliveries for Amazon Prime members, as it will add a $9.95 service fee beginning in October.

FedEx Lead

FedEx Is a Sell, Guilfoyle Says

Delivery giant recently missed estimates and has been late to raise prices.

intel (4)

Intel Starts Construction of Two Arizona Computer Chip Factories

Intel broke ground on two new computer chip factories in Arizona as part of a $20 billion project to help meet the high demand for semiconductors in the U.S.

A technician works with genome samples at a biotech lab in Beijing. Photo: Reuters

Bret Jensen: Two Biotechs to Consider

Things are looking up for these drug companies as they make progress with the FDA